• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Cytori Therapeutics Names John Ransom, Ph.D., Vice President of Research, Regenerative Cell Technology

Posted on: Wednesday, 14 December 2005, 03:00 CST

Cytori Therapeutics, Inc. (Frankfurt: XMPA) announced today the appointment of John Ransom, Ph.D., to Vice President of Research, Regenerative Cell Technology. Dr. Ransom will direct the Company's adipose stem and regenerative cell therapy discovery efforts.

"We look forward to Dr. Ransom leading our next stage of scientific research," stated Marc H. Hedrick, M.D., President of Cytori Therapeutics. "His unique background combines training as a physiologist and immunologist with being a worldwide expert in one of the most important drug targets within biotech, G-protein coupled receptors. This drug discovery experience and leadership will ideally complement our current scientific expertise in stem cells, adipose tissue and cardiovascular disease."

Dr. Ransom has over 17 years of drug discovery management experience. Prior to joining Cytori, Dr. Ransom spent five years at Novasite Pharmaceuticals, Inc., most recently as Vice President, Biology. There he focused on discovery of drug candidates for neuropathic pain, central nervous system disorders and metabolic disease as well as technology development. Dr. Ransom received his Ph.D. in Physiology from University of Texas, Southwestern Medical School.

About Cytori Therapeutics

Cytori Therapeutics, Inc., (Frankfurt: XMPA) is discovering and developing proprietary cell-based therapeutics utilizing adult stem and regenerative cells derived from adipose tissue, also known as fat. The Company's preclinical investigational therapies target cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders and new approaches for aesthetic and reconstructive surgery. To facilitate processing and delivery of adipose stem and regenerative cells, Cytori has developed its proprietary Celution(TM) System to isolate and concentrate a patient's own stem and regenerative cells in about an hour. This system will dramatically improve the speed in which personalized cell-based therapies can be delivered to patients.

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking statements regarding events and trends which may affect Cytori Therapeutics' future operating results, cell therapy product development, and financial position. Such statements are subject to risks and uncertainties that could cause the Company's actual results, product development timelines, and financial position to differ materially. Some of these risks and uncertainties are described (under the heading "Risk Factors") in Cytori Therapeutics' 2004 Form 10-K annual report for the year ended December 31, 2004 and subsequent SEC filings, which are available through the Company's web site. Cytori Therapeutics assumes no responsibility to update any revision of forward-looking statements to reflect events, trends or circumstances after the date they are made.

Source: Business Wire

More News in this Category